skeleton
• osteoblast function is diminished
|
• decrease in osteoclast number in secondary spongiosa
|
• decrease in total bone mineral density, trabecular bone mineral density, trabecular thickness, trabecular number, mineralizing surface, and mineral apposition rate
(J:104382)
• lithium chloride treatment improves bone formation in homozygotes
(J:104382)
• female mice treated with a sclerostin antibody show improvement in bone properties and bone formation
(J:213541)
|
• osteoblast number is reduced
|
• decrease in trabecular bone mineral density, trabecular thickness, and trabecular number
|
• reduction in bone mass because of a deficiency in osteoblast number and function
(J:104382)
|
osteoporosis
(
J:213541
)
• decrease in mineral apposition rate and mineralizing surface
(J:104382)
|
|
• mineral apposition rates and bone formation rates are decreased
(J:213541)
• mineralizing surface per unit bone surface is reduced in femurs
(J:213541)
|
• decrease in bone formation rate
|
• bones show decreased ultimate force, energy to failure, and stiffness, indicating decreased bone strength
|
hematopoietic system
• decrease in osteoclast number in secondary spongiosa
|
immune system
• decrease in osteoclast number in secondary spongiosa
|
cellular
• osteoblast function is diminished
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
osteoporosis-pseudoglioma syndrome | DOID:0060849 |
OMIM:259770 |
J:213541 |